Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics

Core Insights - Amicus Therapeutics (FOLD) is expected to report quarterly earnings of $0.10 per share, reflecting a year-over-year increase of 190.9% [1] - Anticipated revenues for the quarter are projected to be $149.53 million, representing a 29.9% increase compared to the same quarter last year [1] Earnings Estimates Revision - The consensus EPS estimate for the quarter has been revised downward by 80% over the past 30 days, indicating a significant reassessment by analysts [2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock [3] Revenue Projections - Analysts predict 'Net Product Revenues- Galafold' will reach $140.98 million, showing a year-over-year change of +32.3% [5] - 'Geographic revenues- Ex-U.S' are expected to be $94.04 million, indicating a +30.8% change from the previous year [5] - 'Geographic revenues- United States' are forecasted to be $55.85 million, suggesting a +29.4% year-over-year change [5] Stock Performance - Over the past month, Amicus Therapeutics shares have recorded a return of +3.8%, compared to the Zacks S&P 500 composite's +4.7% change [6] - Based on its Zacks Rank 3 (Hold), FOLD is likely to perform in line with the overall market in the upcoming period [6]